Cancer is the primary cause of death worldwide, accounting for almost 10 million deaths. The most prevalent are lung, breast, colorectal, and skin cancer. Cancer does not obey the cell cycle which can lead to the formation of tumors. The biogenic amine histamine is synthesized by histidine. Increased amounts of histamine have been linked to the regulation of several tumors. The histamine receptors (H1, H2, H3, and H4) are distributed throughout the skin, where H1 and H2 are the primary targets for drug therapy. Repurposing of the current antihistamine drugs can be cost-effective, safe medications and allied with lesser adverse effects. Researchers examined Six H1-antihistamines (Cetirizine, clemastine, desloratadine, loratadine, ebastine, and fexofenadine) in a nationwide wide cohort study of all Swedish patients with ten types of immunogenic (melanoma, bladder cancer, kidney, prostate, lung, pancreatic, colorectal, breast cancer, and Hodgkin lymphoma) and six non-immunogenic (thyroid cancer, liver, ovarian, brain cancer and lymphoma) tumors. The study shows that Desloratadine and loratadine upsurge the survival rate for many tumors by inhibiting the growth of tumors and promoting apoptotic cell death. The other H1 receptor antagonist Cloperastine knockdown FGF13 expression which is responsible for anticancer agent cisplatin-resistance and selectively kills HeLa cisR cells. Some findings believe H1 receptor antagonists should be investigated in randomized clinical trials for immunogenic tumors. These drugs can be a curative therapy for several tumors including that prognosis with limited treatment options.